Silence Therapeutics PLC ADR SLN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SLN is a good fit for your portfolio.
News
-
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
-
Thinking about buying stock in SoundHound AI, Intuitive Machines, Iovance Biotherapeutics, Silence Therapeutics, or Altimmune?
-
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
-
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
-
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
-
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
-
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
-
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Trading Information
- Previous Close Price
- $21.62
- Day Range
- $21.39–22.31
- 52-Week Range
- $4.84–27.72
- Bid/Ask
- $16.00 / $23.47
- Market Cap
- $1.01 Bil
- Volume/Avg
- 125,885 / 238,945
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 25.42
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene’s message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 109
Comparables
Valuation
|
Metric
|
SLN
|
ZURA
|
PRTA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 2.66 | 1.97 |
Price/Sales | 25.42 | — | 11.97 |
Price/Cash Flow | — | — | — |
Price/Earnings
SLN
ZURA
PRTA
Financial Strength
|
Metric
|
SLN
|
ZURA
|
PRTA
|
|---|---|---|---|
Quick Ratio | 4.10 | 4.92 | 10.97 |
Current Ratio | 4.56 | 4.97 | 11.24 |
Interest Coverage | −1,521.24 | — | — |
Quick Ratio
SLN
ZURA
PRTA
Profitability
|
Metric
|
SLN
|
ZURA
|
PRTA
|
|---|---|---|---|
Return on Assets (Normalized) | −31.04% | −71.08% | −14.95% |
Return on Equity (Normalized) | — | −139.85% | −18.32% |
Return on Invested Capital (Normalized) | −174.93% | −99.89% | −22.78% |
Return on Assets
SLN
ZURA
PRTA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Khngjfwf | Bvk | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zsyblzvy | Szpfhdv | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vpsprgy | Fnyyw | $97.8 Bil | |
MRNA
| Moderna Inc | Bnqflxzyd | Ggft | $41.3 Bil | |
ARGX
| argenx SE ADR | Bgcsflfht | Wjqvj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Lgzldcsdh | Vgyvb | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qftvlxxy | Tznthh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Cqzvtxgcf | Ntkdn | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fvzwzqqwf | Tdmgf | $12.5 Bil | |
INCY
| Incyte Corp | Pskqrlnfk | Zsjwzp | $11.6 Bil |